Diagnostic criteria and adjudication process both determine published event-rates: The ACTION trial experience

Contemporary Clinical Trials

Volumn 28, Issue 6, 2007, Pages 720-729

  Kirwan, Bridget Anne ^a   Lubsen, Jacobus ^a,b   Brouwer, Sophie de ^a   Danchin, Nicolas ^c   Battler, Alexander ^d   Bayes de Luna, Antonio ^e   Dunselman, Peter H J M ^f   Glasser, Stephen ^g   Koudstaal, Peter J ^b   Sutton, George ^h   van Dalen, Frederik J ^a   Poole Wilson, Philip A ^h  

^a SOCAR RESEARCH SA   (Switzerland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d RABIN MEDICAL CENTER   (Israel)

^e Hospital de la Sta Claret ^*  (Spain)

^f AMPHIA HOSPITAL   (Netherlands)

^g UNIVERSITY OF MINNESOTA   (United States)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical trials; Critical events committee; Diagnostic adjudication procedures; Diagnostic classification; Event rates

Indexed keywords

NIFEDIPINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FATALITY; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; STROKE; TREATMENT OUTCOME;

ADULT; CORONARY ARTERY DISEASE; HUMANS; NIFEDIPINE; PLACEBOS; SENTINEL SURVEILLANCE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 34848892099     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2007.04.001     Document Type: Article

References (10)

1. Mahaffey K.W., Harrington R.A., Akkerhuis M., Kleiman N.S., Berdan L.G., Crenshaw B.S., et al. For the PURSUIT Investigators. Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med 2 (2001) 180-186
2. Lubsen J., Poole-Wilson P.A., Pocock S.J., van Dalen F.J., Baumann J., Kirwan B.A., et al. Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Gastro-intestinal therapeutic system. Eur Heart J 19 Suppl I (1998) I20-I32
3. Poole-Wilson P.A., Lubsen J., Kirwan B.A., van Dalen F.J., Wagener G., Danchin N., et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet 364 (2004) 849-857
4. Center for Drug Evaluation and Research. Coding symbols for thesaurus of adverse reaction terms. Fifth edition (1995), Food and Drug Administration, Rockville, MD
5. Poole-Wilson PA, Kirwan BA, Vokó Z, de Brouwer S, Dunselman PHJM, van Dalen FJ, et al., on behalf of the ACTION investigators. Resource utilisation implications of treatment can be assessed when clinical trial data are reported appropriately. J Clin Epidemiol, doi:10.1016/j.jclinepi.2006.10.016 (published on-line 23 February 2007).
6. Naslund U., Grip L., Fischer-Hansen J., Gundersen T., Lehto S., and Wallentin L. The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. Eur Heart J 20 (1999) 771-777
7. Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Syvertsen J.O., et al. Randomized trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356 (2000) 359-365
8. Brown M.J., Palmer C.R., Castaigne A., de Leeuw P.W., Mancia G., Rosenthal T., et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356 (2000) 366-372
9. Heagerty A., Deverly A., Palmer C., Kaplinsky E., Salvetti A., Wahlgren N.G., et al. The role of the critical event committee in a major cardiovascular outcome study. Blood Press 11 (2002) 339-344
10. Hansson L., Hedner T., and Dahlof B. Prospective Randomized Open Blinded Endpoint (PROBE) study: a novel design for intervention trials. Blood Press 1 (1992) 113-119